75 related articles for article (PubMed ID: 12528777)
1. Piperazine based antimicrobial polymers: a review.
Jalageri MD; Nagaraja A; Puttaiahgowda YM
RSC Adv; 2021 Apr; 11(25):15213-15230. PubMed ID: 35424074
[TBL] [Abstract][Full Text] [Related]
2. Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC).
Joglekar-Javadekar M; Van Laere S; Bourne M; Moalwi M; Finetti P; Vermeulen PB; Birnbaum D; Dirix LY; Ueno N; Carter M; Rains J; Ramachandran A; Bertucci F; van Golen KL
Neoplasia; 2017 Jul; 19(7):564-573. PubMed ID: 28609680
[TBL] [Abstract][Full Text] [Related]
3. Imatinib attenuates cerebrovascular injury and phenotypic transformation after intracerebral hemorrhage in rats.
Pearce WJ; Doan C; Carreon D; Kim D; Durrant LM; Manaenko A; McCoy L; Obenaus A; Zhang JH; Tang J
Am J Physiol Regul Integr Comp Physiol; 2016 Dec; 311(6):R1093-R1104. PubMed ID: 27707720
[TBL] [Abstract][Full Text] [Related]
4. Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE).
Najafzadeh M; Johnston KM; Peacock SJ; Connors JM; Marra MA; Lynd LD; Marra CA
BMC Health Serv Res; 2013 Oct; 13():454. PubMed ID: 24176050
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
[TBL] [Abstract][Full Text] [Related]
6. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.
Yun CH; Boggon TJ; Li Y; Woo MS; Greulich H; Meyerson M; Eck MJ
Cancer Cell; 2007 Mar; 11(3):217-27. PubMed ID: 17349580
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
8. Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy.
Druker BJ
Eur J Cancer; 2002 Sep; 38 Suppl 5():S70-6. PubMed ID: 12528776
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
Kantarjian HM; Talpaz M
Semin Oncol; 2001 Oct; 28(5 Suppl 17):9-18. PubMed ID: 11740802
[TBL] [Abstract][Full Text] [Related]
10. [Tyrosine kinase inhibitors for the treatment of CML].
Heim D
Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.
Hernández-Boluda JC; Cervantes F
Drugs Today (Barc); 2002 Sep; 38(9):601-13. PubMed ID: 12582448
[TBL] [Abstract][Full Text] [Related]
12. Imatinib: the first 3 years.
Capdeville R; Silberman S; Dimitrijevic S
Eur J Cancer; 2002 Sep; 38 Suppl 5():S77-82. PubMed ID: 12528777
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
